Pandemic influenza A(H1N1) 2009 vaccines in the European Union.

作者: P Kramarz , B C Ciancio , K Johansen , A Nicoll

DOI: 10.2807/ESE.14.41.19361-EN

关键词:

摘要: Pandemic vaccines from four manufacturers are now available for use within the European Union (EU). Use of these will protect individuals and reduce impact on health services to more manageable levels. The majority severely ill be known risk groups best strategy start vaccinating in line with recommendation Health Security Committee prioritizing adults children chronic conditions, pregnant women healthcare workers. composition authorized is reviewed this article. vaccine strain all pandemic worldwide based same initial isolate influenza A/California/7/2009 (H1N1)v but differ conditions virus propagation, antigen preparation, content whether they adjuvanted or not. likely effective since no significant genetic antigenic drift has occurred there already mechanisms estimating clinical effectiveness. Influenza have good safety records concerns so far been encountered any developed. However, special devised early detection rigorous investigation possible side effects Europe through post-marketing surveillance analysis. Delivery pose difficulties where those illnesses not readily identifiable services. There considerable scope added value Member States excess making them other states.

参考文章(0)